BlackRock
VIR icon

BlackRock’s Vir Biotechnology VIR Stock Holding History

BlackRock’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211M Buy
20,678,283
+2,679,954
+15% +$25.5M ﹤0.01% 1766
2026
Q1 		$161M Buy
17,998,329
+1,668,226
+10% +$13.3M ﹤0.01% 1797
2025
Q4 		$98.5M Buy
16,330,103
+362,447
+2% +$2.16M ﹤0.01% 2120
2025
Q3 		$91.2M Sell
15,967,656
-185,534
-1% -$949K ﹤0.01% 2157
2025
Q2 		$81.4M Sell
16,153,190
-388,140
-2% -$2.08M ﹤0.01% 2182
2025
Q1 		$107M Buy
16,541,330
+78,613
+0.5% +$699K ﹤0.01% 1944
2024
Q4 		$121M Buy
16,462,717
+86,911
+0.5% +$686K ﹤0.01% 1967
2024
Q3 		$123M Sell
16,375,806
-58,316
-0.4% -$507K ﹤0.01% 1967
2024
Q2 		$146M Sell
16,434,122
-129,490
-0.8% -$1.24M ﹤0.01% 1800
2024
Q1 		$168M Sell
16,563,612
-300,967
-2% -$3.07M ﹤0.01% 1761
2023
Q4 		$170M Buy
16,864,579
+1,060,666
+7% +$9.69M ﹤0.01% 1751
2023
Q3 		$148M Buy
15,803,913
+1,828,956
+13% +$26.1M ﹤0.01% 1746
2023
Q2 		$343M Buy
13,974,957
+19,466
+0.1% +$489K 0.01% 1195
2023
Q1 		$325M Sell
13,955,491
-181,137
-1% -$4.63M 0.01% 1211
2022
Q4 		$358M Buy
14,136,628
+262,902
+2% +$6.44M 0.01% 1113
2022
Q3 		$267M Buy
13,873,726
+1,062,036
+8% +$27M 0.01% 1259
2022
Q2 		$326M Buy
12,811,690
+7,415,506
+137% +$173M 0.01% 1160
2022
Q1 		$139M Buy
5,396,184
+88,135
+2% +$2.61M ﹤0.01% 1919
2021
Q4 		$222M Buy
5,308,049
+148,420
+3% +$5.81M 0.01% 1655
2021
Q3 		$225M Buy
5,159,629
+177,991
+4% +$7.71M 0.01% 1627
2021
Q2 		$236M Sell
4,981,638
-303,802
-6% -$13.8M 0.01% 1643
2021
Q1 		$271M Sell
5,285,440
-163,037
-3% -$8.79M 0.01% 1500
2020
Q4 		$146M Buy
5,448,477
+1,374,316
+34% +$44.7M ﹤0.01% 1838
2020
Q3 		$140M Buy
4,074,161
+212,472
+6% +$9.15M 0.01% 1675
2020
Q2 		$158M Buy
3,861,689
+3,417,871
+770% +$115M 0.01% 1519
2020
Q1 		$15.2M Buy
443,818
+166,769
+60% +$4.48M ﹤0.01% 2750
2019
Q4 		$3.48M Buy
+277,049
New +$3.71M ﹤0.01% 3610

Other funds holding VIR

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

BlackRock's VIR Position: Q2 2026 in Review

BlackRock increased its Vir Biotechnology (VIR) stake by 15% in Q2 2026, buying an estimated $25.5M and bringing the position to 20,678,283 shares worth $211M. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

BlackRock first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $358M in Q4 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • BlackRock held 20,678,283 shares of Vir Biotechnology worth $211M as of Q2 2026.
  • BlackRock bought 2,679,954 Vir Biotechnology shares in Q2 2026, an estimated $25.5M.
  • Vir Biotechnology made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1766 holding.
  • BlackRock first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • BlackRock's Vir Biotechnology position peaked at $358M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.